Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN) will report fourth-quarter and full-year 2025 financial results on Tuesday, February 24, 2026 at 4:30 p.m. ET. The company will host a live conference call and webcast to discuss results and corporate progress.

Live audio will be accessible via the Events section of Day One's Media & Investors page, and an archived replay will be available for 30 days following the event.

News Market Reaction – DAWN

-2.56%

-2.56% Session close to close

In the Feb 10 session, DAWN declined 2.56%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timeline for DAWN’s detailed fourth-quarter and full-year 2025 results on...

Analysis

This announcement sets the timeline for DAWN’s detailed fourth-quarter and full-year 2025 results on February 24, 2026. It follows preliminary OJEMDA revenue and guidance, the Mersana acquisition, and encouraging FIREFLY-1 data, which previously drew constructive market reactions. Investors may focus on how finalized numbers compare with earlier estimates and on updated milestones for the expanded pipeline, using the call to refine views on growth, cash usage, and execution risk.

Key Figures

Earnings call date: February 24, 2026 Earnings call time: 4:30 p.m. ET Webcast replay window: 30 days

3 metrics

Earnings call date February 24, 2026 Scheduled Q4 and full-year 2025 results

Earnings call time 4:30 p.m. ET Start time of conference call and webcast

Webcast replay window 30 days Archived webcast availability after the event

Historical Context

5 past events · Latest: Jan 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 11	Revenue & guidance	Positive	+26.7%	Preliminary 2025 OJEMDA revenue, strong YoY growth, and 2026 guidance.
Jan 06	Acquisition close	Positive	+1.1%	Completion of Mersana acquisition with cash and CVR consideration.
Dec 16	Conference presentation	Neutral	-0.2%	Announcement of CEO presentation at J.P. Morgan Healthcare Conference.
Nov 24	Clinical data update	Positive	+4.2%	Three-year follow-up Phase 2 FIREFLY-1 data for OJEMDA in pLGG.
Nov 18	Conference participation	Neutral	-3.0%	Planned fireside chat at the Piper Sandler Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Fundamental catalysts like revenue updates, guidance, acquisitions, and clinical data have historically drawn positive reactions, while conference participation headlines have seen muted or slightly negative moves.

Recent Company History

Over the last few months, DAWN has reported strong OJEMDA growth, with preliminary 2025 net product revenue and 2026 guidance driving a 26.73% move after the Jan 11 update. The completed Mersana acquisition on Jan 6, 2026 added an ADC program and coincided with a modest gain. Clinical data from FIREFLY-1 on Nov 24, 2025 also supported a positive reaction. In contrast, conference participation updates in late 2025 drew small, mixed price changes, suggesting investors focus more on tangible financial and clinical milestones than on event logistics like today’s earnings-date announcement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025.

Live audio of the webcast will be accessible by visiting the Events section of Day One’s Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days following the event.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer - regardless of age - starting from day one.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301, and following the recently announced acquisition of Mersana Therapeutics, Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).

Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.

DAY ONE MEDIA
media@dayonebio.com

DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

When will Day One (DAWN) report Q4 and full-year 2025 results?

Day One will report results on Tuesday, February 24, 2026 at 4:30 p.m. ET. According to the company, the report will be delivered via a live conference call and webcast to review financials and corporate progress for Q4 and full-year 2025.

How can investors access the Day One (DAWN) earnings webcast on February 24, 2026?

Investors can access the live webcast through the Events section of Day One's Media & Investors page. According to the company, live audio will stream there and the Events page will host the archived replay after the call.

Will Day One (DAWN) provide an archived replay of the February 24, 2026 webcast?

Yes, an archived replay will be available for 30 days following the event. According to the company, the archived version will be posted in the Events section of the Media & Investors page for later review.

What will Day One (DAWN) discuss during the February 24, 2026 conference call?

Day One will discuss fourth-quarter and full-year 2025 financial results and corporate progress. According to the company, management will review recent developments and financial performance during the live call and webcast.

Is live audio the only way to listen to Day One's (DAWN) February 24, 2026 presentation?

Live audio will be available via the company's webcast on the Events page, and an archived replay will follow. According to the company, listeners should use the Events section of the Media & Investors page to access both live and archived audio.